Adam Kalbermatten leads the BD Pharmaceutical Systems Advanced Drug Delivery (ADDS) business. Adam is focused on partnering with pharmaceutical and biotechnology companies to provide drug delivery solutions and services that help commercialize combination product therapies.
Adam previously served as Chief Executive Officer of ZebraSci which was acquired by BD in 2021. Prior to leading the ZebraSci organization, Adam held several leadership roles at Terumo, BD, and Merck. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Masters of Engineering in Engineering Management from Stevens Institute of Technology and a MBA from Columbia University.
